Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 782

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 782
---
 ended September 30, 2024 and 2023 was $7.92 and $93.72, respectively. As of September 30, 2024, the Company’s restricted stock units consist of time-based restricted stock units. All remaining performance-based restricted stock units either vested or were forfeited in the first quarter of 2024. For time-based restricted stock units, the Company recognizes compensation expense associated with these restricted stock units ratably over the award’s vesting period following the grant date. For performance-based restricted stock units, vesting was contingent on the achievement of certain performance targets, subject to the recipient’s continuous service through each performance target. Recognition of compensation expense associated with these performance-based awards began when, and to the extent, the performance criteria were probable of achievement and the employee had met the service conditions. During the three and nine months ended September 30, 2024 and 2023, the Company recognized compensation expense relating to restricted stock units as follows:

| ​                                   
 ​                                   | ​    
 2024 | ​ | Three Months EndedSeptember 30, |   |   ​ | ​ | 2023 |   |   |   |   ​ | ​ | ​    
 2024 | ​ | Nine Months EndedSeptember 30, |   |     ​ | ​ | 2023 |   |   |   |     ​ |   | ​ |
|:------------------------------------|:-----|:--|:--------------------------------|:--|----:|:--|:-----|:--|:--|:--|----:|:--|:-----|:--|:-------------------------------|:--|------:|:--|:-----|:--|:--|:--|------:|:--|:--|
| Research and development            | ​    | ​ | ​                               | $ |   — | ​ | ​    | ​ | ​ | $ |  90 | ​ | ​    | ​ | ​                              | $ |   249 | ​ | ​    | ​ | ​ | $ |   385 | ​ | ​ |
| General and administrative          | ​    | ​ | ​                               | ​ | 353 | ​ | ​    | ​ | ​ | ​ | 410 | ​ | ​    | ​ | ​                              | ​ | 2,036 | ​ | ​    | ​ | ​ | ​ | 1,308 | ​ | ​ |
| Total restricted stock unit expense